CHEMOMAB THERAPEUTICS LTD (CMMB) Fundamental Analysis & Valuation

NASDAQ:CMMB • US16385C2035

Current stock price

1.57 USD
+0.09 (+6.08%)
At close:
1.6 USD
+0.03 (+1.91%)
After Hours:

This CMMB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CMMB Profitability Analysis

1.1 Basic Checks

  • CMMB had negative earnings in the past year.
  • CMMB had a negative operating cash flow in the past year.
  • CMMB had negative earnings in each of the past 5 years.
  • CMMB had a negative operating cash flow in each of the past 5 years.
CMMB Yearly Net Income VS EBIT VS OCF VS FCFCMMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • With a Return On Assets value of -106.24%, CMMB is not doing good in the industry: 77.56% of the companies in the same industry are doing better.
  • The Return On Equity of CMMB (-121.90%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -106.24%
ROE -121.9%
ROIC N/A
ROA(3y)-85.25%
ROA(5y)-73.64%
ROE(3y)-107.28%
ROE(5y)-89.93%
ROIC(3y)N/A
ROIC(5y)N/A
CMMB Yearly ROA, ROE, ROICCMMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • CMMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMMB Yearly Profit, Operating, Gross MarginsCMMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CMMB Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for CMMB has been increased compared to 1 year ago.
  • CMMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMMB Yearly Shares OutstandingCMMB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 1M 2M 3M
CMMB Yearly Total Debt VS Total AssetsCMMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -4.64, we must say that CMMB is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of CMMB (-4.64) is worse than 61.51% of its industry peers.
  • CMMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.64
ROIC/WACCN/A
WACCN/A
CMMB Yearly LT Debt VS Equity VS FCFCMMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • CMMB has a Current Ratio of 7.42. This indicates that CMMB is financially healthy and has no problem in meeting its short term obligations.
  • CMMB has a Current ratio of 7.42. This is in the better half of the industry: CMMB outperforms 69.83% of its industry peers.
  • CMMB has a Quick Ratio of 7.42. This indicates that CMMB is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of CMMB (7.42) is better than 70.21% of its industry peers.
Industry RankSector Rank
Current Ratio 7.42
Quick Ratio 7.42
CMMB Yearly Current Assets VS Current LiabilitesCMMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CMMB Growth Analysis

3.1 Past

  • CMMB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.33%, which is quite impressive.
EPS 1Y (TTM)62.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CMMB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.01% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.46%
EPS Next 2Y15.53%
EPS Next 3Y4.2%
EPS Next 5Y14.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMMB Yearly Revenue VS EstimatesCMMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
CMMB Yearly EPS VS EstimatesCMMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200 -250

More info and screens

Find the best growth stocksShow best growing peers

0

4. CMMB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CMMB. In the last year negative earnings were reported.
  • Also next year CMMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMMB Price Earnings VS Forward Price EarningsCMMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMMB Per share dataCMMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.53%
EPS Next 3Y4.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CMMB Dividend Analysis

5.1 Amount

  • No dividends for CMMB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CMMB Fundamentals: All Metrics, Ratios and Statistics

CHEMOMAB THERAPEUTICS LTD

NASDAQ:CMMB (3/31/2026, 6:35:17 PM)

After market: 1.6 +0.03 (+1.91%)

1.57

+0.09 (+6.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19
Earnings (Next)05-13
Inst Owners5.97%
Inst Owner Change-5.88%
Ins Owners8.95%
Ins Owner Change0%
Market Cap29.60M
Revenue(TTM)N/A
Net Income(TTM)-11.82M
Analysts85
Price Target15.3 (874.52%)
Short Float %5%
Short Ratio0.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.29%
PT rev (3m)-43.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-856.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.05
P/tB 3.05
EV/EBITDA N/A
EPS(TTM)-2.76
EYN/A
EPS(NY)-1.84
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0
BVpS0.51
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -106.24%
ROE -121.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.25%
ROA(5y)-73.64%
ROE(3y)-107.28%
ROE(5y)-89.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.42
Quick Ratio 7.42
Altman-Z -4.64
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)40.38%
Cap/Depr(5y)224.23%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y43.46%
EPS Next 2Y15.53%
EPS Next 3Y4.2%
EPS Next 5Y14.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.06%
OCF growth 3YN/A
OCF growth 5YN/A

CHEMOMAB THERAPEUTICS LTD / CMMB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CHEMOMAB THERAPEUTICS LTD?

ChartMill assigns a fundamental rating of 2 / 10 to CMMB.


Can you provide the valuation status for CHEMOMAB THERAPEUTICS LTD?

ChartMill assigns a valuation rating of 0 / 10 to CHEMOMAB THERAPEUTICS LTD (CMMB). This can be considered as Overvalued.


How profitable is CHEMOMAB THERAPEUTICS LTD (CMMB) stock?

CHEMOMAB THERAPEUTICS LTD (CMMB) has a profitability rating of 0 / 10.